A number of leading biomedical experts will address topics relating to precision medicine during the second edition of the Qatar Biobank Congress, which takes place from March 14 - 15 at the Qatar National Convention Centre (QNCC).
Held under the theme ‘The Impact of Biobanking on Precision Medicine Initiatives’, the conference will bring together top medical practitioners and researchers in biobanking, genomics and personalized medicine to discuss the field of biomedical science and the growing use of precision medicine to improve clinical outcomes.
On the first day of the conference, Dr. Asmaa Al Thani, Chair of Qatar Genome Programme Committee and Board Vice Chairperson of Qatar Biobank, will explain how the Qatar Population Biobank Project aims to establish a research enterprise platform to achieve significant improvement in diagnostic and prognostic intelligence required to deliver personalized healthcare.
Addressing the topic of ‘Population Biobanks: Goals and Perspectives’, Professor Elio Riboli, Professor of Cancer Epidemiology and Prevention at Imperial College London, will highlight how population cohorts have greatly contributed to increased scientific understanding of the causes of chronic diseases. Prof. Riboli will offer key insights into the unique role of cohorts in research focused on the interaction between genetic and epigenetic characteristics in combination with environmental exposures and endogenous and metabolic characteristics.
Professor Khawla Al-Kuraya will deliver a paper entitled ‘Genomic Cancer Research: Identification of Molecular Signature of Common Diseases’ that will examine how the study of different human populations offers insights into disease pathogenesis, based on genomic analysis of colorectal cancer in Saudi Arabian patients.
During the panel discussion on ‘The Importance of Human Disease Biobank’, Professor Peter Riegman of Erasmus University in Rotterdam, Netherlands, will present his paper on ‘Tissue Bank and Digital Pathology’. The session will explore the role of tissue banking in accessing the promises of precision or personalized medicine, especially where new targets need to be discovered for new therapies, accompanied by the need for the discovery of new biomarkers.
For the full story, please click here